Galera Therapeutics, Inc.
GRTXOTCHealthcare● Active
$0.09
$-0.00(-4.09%)
Market Cap$6678571
P/E Ratio—
52W High$0.15
52W Low$0.015
Galera Therapeutics, Inc. (GRTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GRTX · earnings · updated Jun 15, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.01
Est. -$0.83 · +98.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS🔥 4-Quarter EPS Beat Streak
GRTX reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
79
days
Expected Date
Sep 2, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.18
Rev. $6.96B
Days Away79
Expected DateSep 2, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.18
Rev. Est.$6.96B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.77 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.83 | -$0.01 | +98.8% | — | — | — |
| ▲ Q1 FY2026 | Mar 19, 2026 | -$0.30 | $0.66 | +320.0% | — | — | — |
| — Q4 FY2025 | Nov 13, 2025 | — | -$0.01 | — | — | — | — |
| — Q3 FY2025 | Aug 13, 2025 | — | -$0.01 | — | — | — | — |
| — Q2 FY2025 | May 15, 2025 | — | -$0.01 | — | — | — | — |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.30 | -$0.08 | +73.3% | — | — | — |
| ▲ Q4 FY2024 | Dec 13, 2024 | -$0.29 | -$0.06 | +79.3% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.77
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.01
EPS Est.
-$0.83
EPS Surpr.
+98.8%
Revenue
—
Q1 FY2026
Mar 19, 2026Beat
EPS Actual
$0.66
EPS Est.
-$0.30
EPS Surpr.
+320.0%
Revenue
—
Q4 FY2025
Nov 13, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 13, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 15, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.30
EPS Surpr.
+73.3%
Revenue
—
Q4 FY2024
Dec 13, 2024Beat
EPS Actual
-$0.06
EPS Est.
-$0.29
EPS Surpr.
+79.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q4 FY2029 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q3 FY2029 | $0.83 | $0.83 | $0.83 | 1 |
| Q2 FY2029 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q1 FY2029 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q4 FY2028 | $-0.40 | $-0.40 | $-0.40 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2029 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2029 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +98.8% | $0.10 | $0.10 | -0.50% |
| ▲ Q1 FY2026 | Mar 19, 2026 | +320.0% | $0.05 | $0.05 | -1.00% |
| — Q4 FY2025 | Nov 13, 2025 | — | $0.02 | $0.02 | -1.25% |
| — Q3 FY2025 | Aug 13, 2025 | — | $0.02 | $0.02 | -2.80% |
| — Q2 FY2025 | May 15, 2025 | — | $0.02 | $0.02 | +0.00% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +73.3% | $0.03 | $0.03 | -9.09% |
| ▲ Q4 FY2024 | Dec 13, 2024 | +79.3% | $0.03 | $0.03 | -4.46% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -108.5% | $0.05 | $0.07 | +33.46% |
Q2 FY2026-0.50%
Report Date
May 14, 2026
EPS Beat/Miss
+98.8%
Price Before
$0.10
Price After
$0.10
Q1 FY2026-1.00%
Report Date
Mar 19, 2026
EPS Beat/Miss
+320.0%
Price Before
$0.05
Price After
$0.05
Q4 FY2025-1.25%
Report Date
Nov 13, 2025
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q3 FY2025-2.80%
Report Date
Aug 13, 2025
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q2 FY2025+0.00%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q1 FY2025-9.09%
Report Date
Mar 31, 2025
EPS Beat/Miss
+73.3%
Price Before
$0.03
Price After
$0.03
Q4 FY2024-4.46%
Report Date
Dec 13, 2024
EPS Beat/Miss
+79.3%
Price Before
$0.03
Price After
$0.03
Q3 FY2024+33.46%
Report Date
Aug 14, 2024
EPS Beat/Miss
-108.5%
Price Before
$0.05
Price After
$0.07
Avg Beat Reaction-3.76%
Avg Miss Reaction+33.46%
Beat Rate4 / 8 quarters
Largest Move+33.46% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GRTX ends December
Galera Therapeutics, Inc. (GRTX) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.01 — beating the analyst consensus of $-0.83 by +98.8%. GRTX has beaten EPS estimates for 4 consecutive quarters. The next GRTX earnings date is expected around September 2, 2026.
Each quarter, investors track GRTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GRTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GRTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GRTX earnings · 5 questionsGalera Therapeutics, Inc.'s next earnings report is expected around September 2, 2026. GRTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GRTX historically reports after market close (AMC).
GRTX earnings datewhen is GRTX earningsGRTX next earnings datewhen does GRTX report earningsGRTX earnings calendar
▸ Source: FMP · Galera Therapeutics, Inc. SEC filings · US GAAP · Galera Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026